Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say

Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say
The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA — a group of major U.S. pharmaceutical companies — recently released a list of treatments currently in clinical development for Alzheimer’s, along with a “Medicines in Development 2017 Update” to reassure patients and caregivers that all these failed trials have advanced disease understanding, and that this is reflected in new efforts. But what does this list of more than 80 drugs in testing tell us? Do these trials hold a promise to deliver where others have not? And what exactly have scientists learned from the 123 treatments that failed in clinical studies since 1998? To find out, Alzheimer’s News Today spoke separately to two Alzheimer’s researchers and experts. “We absolutely are working with the highest sense of urgency to try to bring effective therapies to patients. But it is a long road of learning,” said Dr. Matthew Kennedy, director of Early Discovery, Neuroscience, at Merck and a PhRMA representative.  “I'm very excited about what the next few years might bring.” Dr. Dean Hartley, director of scientific initiatives at the Alzheimer's Association, agrees that a breakthrough may
Subscribe or to access all post and page content.